AOAC Home

Task Force Home

Marine & Freshwater Toxins

Task Force Membership

Terms of Reference


Presidential Task Force on Marine and Freshwater Toxins

Analytical Methods Criteria for Prioritization and Selection


TO PRIORITIZE ORDER IN WHICH TOXINS/METHODS SHOULD BE ADDRESSED BY TASK FORCE

Need for Method - Demonstrated human illnesses due to toxin(s), with higher priority given for toxins known to cause human fatalities. Other impacts can include extensive economic damage and economic/cultural impact on subsistence groups. The method satisfies a recognized (public health related) need, for example it is given higher priority if there is no other method of analysis for toxins known to impact human health. Method may be needed to be able to fulfill national, regional, or international regulations, and limits exist which cannot be easily enforced. Higher priority is given to detection of toxins with greater potential for bioterrorist acts against the food and water supply.

Priorities of Outside Groups - The priority level of the method or method area is increased when International and/or influential groups (CODEX, UNESCO, FAO, EU, FDA, etc) have published documents expressing priority need for methodology in this toxin category.

Animal Assays/Legality Issues – Provides alternative to animal bioassay.

Full AOAC Method Performance Interlaboratory Study Exists – This is a special case, where higher priority can be given (still considering the criteria above) in that the results of an interlaboratory study are known. However the method must meet basic AOAC OMA criteria (this consideration is a special case at this point in time, June 2004, given current existence of such studies and also small number of approved AOAC methods for marine and freshwater toxins)


TO SELECT MOST APPROPRIATE METHODS FOR VALIDATION AND GUIDE METHODS DEVELOPMENT

Method Performance

  1. Method response to analyte can be related to toxin levels or activities of interest for toxin forms known to impact public health. Thus, the specificity desired is based on toxin class and known toxicity of individual forms and the method responds to toxin forms within a chemical class that make a significant contribution to overall toxicity. For assays (methods responding to total binding, biochemical or biological activity, etc.) the response parallels the overall toxicity.

  2. Dynamic Range of response, linear or otherwise, is adequate for purpose of clearly determining if analyte(s)/activity are above or below the level of interest. Determination Limit allows detection of total concentrations of currently known, impact-significant toxin forms or activities below action level (2x below [or lower if appropriate] for screening, 5x for quantitation).

  3. Recovery studies conducted in the sample matrix of interest. If available, naturally contaminated samples (analyzed by independent methodology) or analysis of Certified Reference Materials has been used to demonstrate adequate selectivity in the applicable sample matrix.

  4. AOAC Single Laboratory Validation (SLV) is preferred. Equivalent data accepted if it satisfies requirements for AOAC SLV study. Repeatability precision is acceptable as per SLV standards.

  5. Ruggedness - Critical (least rugged) parameters have been identified via ruggedness testing and are taken into account in method procedure, cautions, etc.

  6. Standards - Accurate calibration standards, and ideally, certified reference materials (CRMs), are readily available for implementation of the method as well as for routine validation and performance testing. Since calibration standards may not be available for all toxin forms in a group, the establishment and evaluation of relative response factors must be documented.

Practicality
Throughput meets program needs of stakeholders, and instrumentation, standards, techniques, etc. within budget or expertise limitations of stakeholder laboratories. Results are in units that allow use with action levels. If the method is proprietary, is that problematic in terms of availability of materials, continuity of method performance (e.g., reproducible production of antibodies), predicting performance in untested sample matrices, or in knowing critical parameters impacting ruggedness?





Copyright © 2009 AOAC INTERNATIONAL. All Rights Reserved.
Comments, Questions, Concerns, e-mail webmaster@aoac.org.